Alliqua, Inc. (ALQA)
-OTC Markets 0.07 
0.01(10.00%) May 17, 3:36PM EDT
| Prev Close: | 0.06 |
|---|
| Open: | 0.06 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.17 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.06 - 0.07 |
|---|
| 52wk Range: | 0.03 - 0.10 |
|---|
| Volume: | 186,112 |
|---|
| Avg Vol (3m): | 587,608 |
|---|
| Market Cap: | 17.42M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.02 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ALLIQUA, INC. Files SEC form 10-Q/A, Quarterly ReportEDGAR Online(Thu, May 16)
- ALLIQUA, INC. Files SEC form 10-K/A, Annual ReportEDGAR Online(Thu, May 16)
- ALLIQUA, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- Alliqua to Present Results Demonstrating Antimicrobial Properties of SilverSeal® at SAWC SPRING 2013PR Newswire(Thu, May 2)
- ALLIQUA, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and ExhibitsEDGAR Online(Fri, Apr 26)
- ALLIQUA, INC. FinancialsEDGAR Online Financials(Sat, Apr 20)
- ALLIQUA, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Tue, Apr 16)
- Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound IndicationsPR Newswire(Fri, Mar 22)
- Letter from Alliqua CEO, Dave Johnston, to ShareholdersPR Newswire(Thu, Mar 7)
- ALLIQUA, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and ExhibitsEDGAR Online(Mon, Feb 25)
- Recognizing Leadership In Biotech: A Critical Facet Of The Diligence Processat Seeking Alpha(Thu, Feb 21)
- ALLIQUA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Tue, Feb 12)
- Alliqua Demonstrates Wound Healing Benefit of SilverSeal® Dressing on Foot and Ankle Post-Surgical WoundsPR Newswire(Mon, Feb 11)
- ALLIQUA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial StatEDGAR Online(Thu, Feb 7)
- Alliqua Strengthens and Realigns Executive TeamPR Newswire(Tue, Feb 5)
Reports
- No Reports available for ALQA at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 12.89 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Alliqua, Inc., a biopharmaceutical company, focuses on the development, manufacture, and distribution of proprietary transdermal wound care and drug delivery technologies.
View More